KSC Healthcare Drug Manufacturers - Specialty & Generic 185750.KS

Chong Kun Dang Pharmaceutical Corp.

$ 69 900.00 -1.69 %

Chong Kun Dang Pharmaceutical Corp. develops, promotes, and distributes a comprehensive array of medical and health-related goods. The company operates extensively, catering to the South Korean domestic market and extending its reach internationally through exports. Its offerings encompass critical prescription drugs, such as treatments for high blood pressure, high cholesterol, and diabetes. Additionally, it provides popular over-the-counter remedies like Penzal, Prefemine, and Modcol, alongside various consumer health commodities including insecticides and hair dyes. A significant part of its portfolio also includes health supplements aimed at disease prevention. Established in 1941, Chong Kun Dang Pharmaceutical Corp. maintains its principal office in Seoul, South Korea.

CEO: Young-Joo Kim - https://www.ckdpharm.com

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

-

Recommandation

-

DCF

$ 142 301.42

Loading data...

185750.KS vs S&P500

Loading data...

No data available.

Quick ratio

1.15

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

0.00

may indicate that the company is undervalued or has poor growth prospects.

EPS

0.00

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

8.09 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

5.35 %

generates a return higher than the cost of its capital, thereby creating value for its investors.

WACC

4.71

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.36

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

-8 168.33

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

17.60 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
4 indicates moderate financial health
Altman score
2.14 indicates an uncertain financial situation
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.33 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.20 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.